DK3042205T3 - Fremgangsmåde til forbedring af antistofstabilitet - Google Patents

Fremgangsmåde til forbedring af antistofstabilitet Download PDF

Info

Publication number
DK3042205T3
DK3042205T3 DK14758893.3T DK14758893T DK3042205T3 DK 3042205 T3 DK3042205 T3 DK 3042205T3 DK 14758893 T DK14758893 T DK 14758893T DK 3042205 T3 DK3042205 T3 DK 3042205T3
Authority
DK
Denmark
Prior art keywords
antibody stability
improving antibody
improving
stability
antibody
Prior art date
Application number
DK14758893.3T
Other languages
English (en)
Inventor
Hubert Kettenberger
Stefan Klostermann
Apollon Papadimitriou
Florian Lipsmeier
Jasmin Sydow-Andersen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK3042205T3 publication Critical patent/DK3042205T3/da

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20—Protein or domain folding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C99/00—Subject matter not provided for in other groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Theoretical Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Evolutionary Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Computing Systems (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK14758893.3T 2013-09-06 2014-09-03 Fremgangsmåde til forbedring af antistofstabilitet DK3042205T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13183389 2013-09-06
EP13184174 2013-09-12
PCT/EP2014/068649 WO2015032776A1 (en) 2013-09-06 2014-09-03 Method for improving antibody stability

Publications (1)

Publication Number Publication Date
DK3042205T3 true DK3042205T3 (da) 2020-03-02

Family

ID=51485608

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14758893.3T DK3042205T3 (da) 2013-09-06 2014-09-03 Fremgangsmåde til forbedring af antistofstabilitet

Country Status (10)

Country Link
US (2) US10418126B2 (da)
EP (2) EP3042205B1 (da)
JP (1) JP6580570B2 (da)
KR (1) KR20160052562A (da)
CN (1) CN105518461B (da)
CA (1) CA2918191A1 (da)
DK (1) DK3042205T3 (da)
MX (1) MX2016002720A (da)
RU (1) RU2711719C2 (da)
WO (1) WO2015032776A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016001854A (es) 2013-08-12 2016-09-06 Genentech Inc Composiciones y metodo para tratar condiciones asociadas con el complemento.
SG11201608868PA (en) 2014-05-01 2016-11-29 Genentech Inc Anti-factor d antibody variants and uses thereof
TW201730211A (zh) 2015-10-30 2017-09-01 建南德克公司 抗因子d抗體及結合物
JP2018536650A (ja) * 2015-10-30 2018-12-13 ジェネンテック, インコーポレイテッド 抗d因子抗体変異体コンジュゲート及びその使用
WO2021025940A1 (en) * 2019-08-02 2021-02-11 Genentech, Inc. Prediction of side-chain degradation in polymers through physics based simulations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US100736A (en) * 1870-03-15 dundeedale
RU2134724C1 (ru) * 1992-08-24 1999-08-20 Ниссин Сокухин Кабусики Кайся Гуманизированное антитело и способ его получения, полинуклеотид (варианты), гибридомная клеточная линия (варианты)
AU2005287557B2 (en) * 2004-09-21 2011-10-13 Biontech Ag Use of microproteins as tryptase inhibitors
EA015992B1 (ru) * 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
NZ579594A (en) * 2007-03-12 2012-03-30 Esbatech Alcon Biomed Res Unit Sequence based engineering and optimization of single chain antibodies
PL2307455T3 (pl) * 2008-06-25 2017-09-29 Esbatech, An Alcon Biomedical Research Unit Llc Optymalizacja rozpuszczalności cząsteczek immunowiążących
KR102000383B1 (ko) * 2009-09-29 2019-07-15 유니버시테이트 젠트 만노스-1-포스포-6-만노스 결합의 포스포-6-만노스로의 가수분해
RU2688349C2 (ru) * 2014-03-21 2019-05-21 Ф. Хоффманн-Ля Рош Аг In vitro прогнозирование времени полужизни антител in vivo
US20170175098A1 (en) * 2014-03-28 2017-06-22 Novozymes A/S Enzyme Variants and Polynucleotides Encoding Same
CA2950273C (en) * 2014-05-30 2022-06-21 Novozymes A/S Variants of gh family 11 xylanase and polynucleotides encoding same

Also Published As

Publication number Publication date
EP3761033A3 (en) 2021-01-20
RU2711719C2 (ru) 2020-01-21
JP6580570B2 (ja) 2019-09-25
WO2015032776A1 (en) 2015-03-12
RU2016111352A3 (da) 2018-05-23
RU2016111352A (ru) 2017-10-11
KR20160052562A (ko) 2016-05-12
CN105518461A (zh) 2016-04-20
US20200066372A1 (en) 2020-02-27
US20160275238A1 (en) 2016-09-22
EP3042205B1 (en) 2019-12-25
US10418126B2 (en) 2019-09-17
HK1223684A1 (zh) 2017-08-04
CN105518461B (zh) 2018-04-13
CA2918191A1 (en) 2015-03-12
EP3761033A2 (en) 2021-01-06
EP3042205A1 (en) 2016-07-13
JP2016530288A (ja) 2016-09-29
MX2016002720A (es) 2016-06-08

Similar Documents

Publication Publication Date Title
IL243311A0 (en) Novel antibody frameworks
DK3083540T3 (da) Fremgangsmåde til fremstilling af substituerede phenoxyphenylketoner
DK3736291T5 (da) Anti-FCRH5-antistoffer
DK3708583T3 (da) Ikke-fucosylerede anti-fgfr2iiib-antistoffer
EP3083682C0 (en) DOUBLE SPECIFICITY ANTIBODIES
LT3049441T (lt) Anti-pdl1 antikūnų kompozicija
DK3071595T3 (da) Humaniseret anti-kallikrein-2-antistof
FI20135292L (fi) Menetelmä kartongin valmistamiseksi
DK2972353T3 (da) Forbedrede fremgangsmåder til udførelse af multipleksanalyser
DK3300610T3 (da) Fremgangsmåde til fraktionering af opløselige ærter
DK2996556T3 (da) System til billedstyret procedure
DK3016991T3 (da) Sammensætninger til formning af væsker
DK3068800T3 (da) FcRn-specifikke antistoffer
DK2969098T3 (da) Fremgangsmåder til oprensning af antistoffer
DK3332813T3 (da) Metode til opregulering af antigenekspression
DK3033708T3 (da) Fremgangsmåde til evaluering af et dokument
HRP20190085T1 (hr) Anti-cd52 protutijela
BR112015021083A2 (pt) método
DK2983680T3 (da) Forbedring af organer til transplantation
DK3083493T3 (da) Fremgangsmåde til fremstilling af syntesegas
DK3065774T3 (da) Anti-CCL17-antistoffer
BR112015029076A2 (pt) método
DK3024576T3 (da) Fremgangsmåde til opstart af en fischer-tropsch-proces
DK3016682T3 (da) Metoder til behandling af kræft
DK2786852T3 (da) Metode til laminering af rørfolie